keyword
MENU ▼
Read by QxMD icon Read
search

Entecavir

keyword
https://www.readbyqxmd.com/read/29335905/influence-of-antiviral-therapy-on-the-liver-stiffness-in-chronic-hbv-hepatitis
#1
Luca Rinaldi, Antonio Ascione, Vincenzo Messina, Valerio Rosato, Giovanna Valente, Vincenzo Sangiovanni, Rosa Zampino, Aldo Marrone, Luca Fontanella, Nicolina de Rosa, Pasquale Orabona, Carmela Buonomo, Antonio Chirianni, Luigi Elio Adinolfi, Guido Piai
PURPOSE: The aim of this study was to evaluate the effects of antiviral therapy on liver stiffness measurement (LSM). METHODS: Two hundred HBV patients were enrolled from four hospital centers in southern Italy; median age was 50.7 (25-75) males were 68%; 171 patients underwent to liver biopsy and 200 patients had LSM at baseline and 189 at the end of follow-up. One hundred and forty-nine patients were treated with nucleos(t)ide analogs, while 51 patients were untreated...
January 15, 2018: Infection
https://www.readbyqxmd.com/read/29327822/efficacy-and-safety-of-long-term-entecavir-therapy-in-a-european-population
#2
Alessandro Collo, Paola Belci, Sharmila Fagoonee, Lucia Loreti, Valeria Gariglio, Ramona Parise, Paola Magistroni, Marilena Durazzo
BACKGROUND: Therapy in chronic hepatitis B (CHB) patients aims at improving their survival by preventing disease progression to cirrhosis and its complications. Entecavir (ETV) is currently a first line therapeutic agent recommended for the treatment of CHB. Our aim was to evaluate the long term outcome of a cohort of CHB patients treated with ETV. METHODS: Thirty-four patients treated with ETV for at least 6 months were included in this study. The virologic response was determined by the dosage of serum HBV-DNA, HBsAg, HBeAg, anti-HBs and anti-HBe antibodies...
January 10, 2018: Minerva Gastroenterologica e Dietologica
https://www.readbyqxmd.com/read/29325289/-optimal-treatment-regimen-for-patients-with-hbeag-positive-chronic-hepatitis-b-after-suboptimal-response-to-24-weeks-of-peg-ifn-%C3%AE-2a
#3
X D Luo, X P Chen, X F Chen
Objective: To investigate the optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B (CHB) after suboptimal response to 24 weeks of pegylated interferon (Peg-IFN) α-2a. Methods: A total of 188 patients with HBeAg-positive CHB who had suboptimal response to 24 weeks of Peg-IFN α-2a were randomly divided into entecavir group (n = 93) and telbivudine group (n = 95). The two groups received entecavir 0.5 mg/d and telbivudine 0.6 g/d, respectively, for 208 weeks. After 208 weeks of treatment, the following indices were assessed: HBeAg clearance rate and seroconversion rate, hepatitis B virus (HBV) DNA clearance rate (HBV DNA < 500 IU/ml), safety, and drug resistance rate...
December 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29325275/-qualitative-pathological-assessment-of-liver-fibrosis-regression-after-antiviral-therapy-in-patients-with-chronic-hepatitis-b
#4
Y M Sun, J L Zhou, L Wang, X N Wu, Y P Chen, H X Piao, L G Lu, W Jiang, Y Q Xu, B Feng, Y M Nan, W Xie, G F Chen, H W Zheng, H Li, H G Ding, H Liu, F D Lyu, C Shao, T L Wang, X J Ou, B Q Wang, S Y Chen, H You, J D Jia
Objective: To investigate the methods for qualitative pathological assessment of dynamic changes in liver fibrosis/cirrhosis after antiviral therapy in patients with chronic hepatitis B (CHB), since antiviral therapy can partially reverse liver fibrosis and cirrhosis caused by hepatitis B and semi-quantitative, rather than qualitative, pathological assessment is often used for the research on liver fibrosis regression. Methods: Previously untreated CHB patients with liver fibrosis and cirrhosis were enrolled, and liver biopsy was performed before treatment and at 78 weeks after the antiviral therapy based on entecavir...
November 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29316069/entecavir-and-tenofovir-reduce-hepatitis-b-virus-related-hepatocellular-carcinoma-recurrence-more-effectively-than-other-antivirals
#5
Hyeki Cho, Hongkeun Ahn, Dong Hyeon Lee, Jeong-Hoon Lee, Yong Jin Jung, Young Chang, Joon Yeul Nam, Young Youn Cho, Dong Ho Lee, Eun Ju Cho, Su Jong Yu, Jeong Min Lee, Yoon Jun Kim, Jung-Hwan Yoon
Nucleos(t)ide analogues (NAs) have been shown to decrease the risk of hepatocellular carcinoma (HCC) recurrence. This study evaluated whether high-potency NAs (entecavir and tenofovir disoproxil fumarate [TDF]) reduce the risk of tumor recurrence more potently than low-potency NAs after curative treatment of hepatitis B virus (HBV)-related HCC. This study included 607 consecutive HBV-related HCC patients treated with surgical resection or radiofrequency ablation. The patients were categorized into three groups according to antiviral treatment: group A (no antiviral; n=261), group B (low-potency NA; n=90), and group C (high-potency NA; n=256)...
January 6, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29314465/sequential-therapy-involving-an-early-switch-from-entecavir-to-pegylated-interferon-%C3%AE-in-japanese-patients-with-chronic-hepatitis-b
#6
Masaru Enomoto, Shuhei Nishiguchi, Akihiro Tamori, Ritsuzo Kozuka, Hideki Fujii, Sawako Uchida-Kobayashi, Shinya Fukunishi, Yasuhiro Tsuda, Kazuhide Higuchi, Masaki Saito, Hirayuki Enomoto, Norifumi Kawada
AIM: The optimal combination of the two currently available agents with different mechanisms of action, a nucleos(t)ide analog and pegylated interferon-α (PegIFNα), must be determined to improve treatment of chronic hepatitis B. METHODS: In this study, 24 patients with chronic hepatitis B (14 hepatitis B e-antigen [HBeAg]-positive and 10 HBeAg-negative) received entecavir for 36-52 weeks, followed by entecavir plus PegIFNα-2a for 4 weeks and finally by PegIFNα-2a alone for 44 weeks...
January 4, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29314359/chiral-detection-of-entecavir-stereoisomeric-impurities-by-forming-a-complex-with-r-besivance-and-znii-using-mass-spectrometry
#7
Yali Wang, Lu Wang, Xiaolei Chen, Cuirong Sun, Yixin Zhu, Yu Kang, Su Zeng
In this study, a mass spectrometry (MS)-based kinetic method (KM) is shown to be successful at analyzing a multi-chiral center drug stereoisomer, entecavir (ETV), both qualitatively and quantitatively. On the basis of the KM, the bivalent complex ion [MII (A)(ref*)2 ]2+ (MII =divalent metal ion, A=analyte, ref*=chiral reference) was set as precursor ion in MS/MS. The experiment results suggest strong chiral selectivity between ETV and its isomers when using ZnII coordinated with the chiral reference R-besivance (R-B)...
January 4, 2018: Journal of Mass Spectrometry: JMS
https://www.readbyqxmd.com/read/29309397/assessment-of-bone-mineral-density-in-patients-with-cirrhosis-treated-with-third-generation-nucleos-t-ide-analogues-comparison-between-tenofovir-and-entecavir
#8
Marta Tonon, Salvatore Piano, Antonietta Romano, Silvano Fasolato, Marialuisa Stanco, Chiara Pilutti, Patrizia Pontisso, Sara Mareso, Carmine Gambino, Leonardo Sartori, Paolo Angeli
BACKGROUND AND AIM: Tenofovir and entecavir are nowadays the first-line treatment in hepatitis B virus (HBV)-related cirrhosis. Both drugs were shown to be effective in HBV suppression and well tolerated. The effects of tenofovir on bone mineral density (BMD), however, were shown to worsen the rate of osteoporosis, which is already a common feature in cirrhosis. In contrast, entecavir seems to have no effect on mineral metabolism. The aim of our study was to compare the effects of nucleos(t)ide analogs on bone density in HBV-related cirrhosis...
January 5, 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29303483/uptake-of-tenofovir-based-antiretroviral-therapy-among-hiv-hbv-coinfected-patients-in-the-eurosida-study
#9
Lars Peters, Amanda Mocroft, Daniel Grint, Santiago Moreno, Alexandra Calmy, Djordje Jevtovic, Helen Sambatakou, Karine Lacombe, Stephane De Wit, Jürgen Rockstroh, Jelena Smidt, Igor Karpov, Anna Grzeszczuk, Vesnadarjan Haziosmanovic, Magnus Gottfredsson, Roxana Radoi, Elena Kuzovatova, Chloe Orkin, Anna Lisa Ridolfo, Jose Zapirain, Jens Lundgren
BACKGROUND: According to guidelines all HIV/HBV co-infected patients should receive tenofovir-based combination antiretroviral therapy (cART). We aimed to investigate uptake and outcomes of tenofovir-based cART among HIV/HBV patients in the EuroSIDA study. METHODS: All HBsAg+ patients followed up after 1 March 2002 were included. Changes in the proportion taking tenofovir-based cART over time were described. Poisson regression was used to investigate the relationship between tenofovir use and clinical events...
January 5, 2018: Antiviral Therapy
https://www.readbyqxmd.com/read/29300980/distinct-relapse-rates-and-risk-predictors-after-discontinuing-tenofovir-and-entecavir-therapy
#10
Tung-Hung Su, Hung-Chih Yang, Tai-Chung Tseng, Jyh-Ming Liou, Chen-Hua Liu, Chi-Ling Chen, Pei-Jer Chen, Ding-Shinn Chen, Chun-Jen Liu, Jia-Horng Kao
Background: We investigated the patterns; predictors for virological relapse (VR), clinical relapse (CR), sustained clinical response (SCR); and retreatment outcomes after nucleos(t)ide analogue (NUC) therapy discontinuation. Methods: Chronic hepatitis B patients discontinuing NUC were prospectively enrolled. Viral and host predictors, including HBsAg, anti-HBc, the single nucleotide polymorphisms of NTCP (rs2296651), CTLA4 (rs231775), rs3077 (HLA-DPA1), and rs9277535 (HLA-DPB1), and post-therapy predictors were investigated...
January 2, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29288943/design-synthesis-and-evaluation-of-novel-phenyl-propionamide-derivatives-as-non-nucleoside-hepatitis-b-virus-inhibitors
#11
Jingying Qiu, Qineng Gong, Jian Gao, Wang Chen, Yinpeng Zhang, Xiaoke Gu, Daoquan Tang
As an ongoing search for potent non-nucleoside anti-HBV agents with novel structures, we described a series of phenyl propionamide derivatives (3a-b, 4a-e, 7a-g, 8a-h and 9a-b) by pharmacophore fusion strategy in the present work. All the compounds exhibited an anti-HBV activity to some extent. Among them, compounds 8d and 9b displayed most potent anti-HBV activity with IC50 values on HBV DNA replication of 0.46 and 0.14 μM, respectively. And the selective index values of 8d and 9b were more than 217.39 and 153...
December 16, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29288305/high-levels-of-serum-mac-2-binding-protein-glycosylation-isomer-m2bpgi-predict-the-development-of-hepatocellular-carcinoma-in-hepatitis-b-patients-treated-with-nucleot-s-ide-analogues
#12
Noboru Shinkai, Masanori Nojima, Etsuko Iio, Kayoko Matsunami, Hidenori Toyoda, Shuko Murakami, Takako Inoue, Shintaro Ogawa, Takashi Kumada, Yasuhito Tanaka
BACKGROUND: Nucleot(s)ide analogues (NA) can reduce the risk of hepatocellular carcinoma (HCC), but not completely prevent its development. METHODS: Two hundred and thirty-four chronic hepatitis B patients virologically well controlled with entecavir or tenofovir disoproxil fumarate for more than 1 year were enrolled in this study. Over the median observation period of 51 (12-142) months, 24 of 234 patients developed HCC. We quantified HBV markers, alpha-fetoprotein (AFP) and Mac-2-binding protein glycosylation isomer (M2BPGi) at baseline and 48 weeks after therapy...
December 29, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/29288020/long-term-incidence-and-predictors-of-hepatitis-b-surface-antigen-loss-after-discontinuing-nucleoside-analogues-in-non-cirrhotic-chronic-hepatitis-b-patients
#13
Chien-Hung Chen, Chao-Hung Hung, Jing-Houng Wang, Sheng-Nan Lu, Tsung-Hui Hu, Chuan-Mo Lee
OBJECTIVES: This study investigates the long-term incidence and predictors for hepatitis B surface antigen (HBsAg) loss after nucleoside analogue (NA) therapy. METHODS: The study included 411 non-cirrhotic chronic hepatitis B (CHB) patients (148 hepatitis B e antigen (HBeAg)-positive and 263 HBeAg-negative patients) who were treated with lamivudine (n=110) or entecavir (n=301) with post-treatment follow-up of at least 12 months. RESULTS: In HBeAg-positive patients, the 8-year cumulative rates of virological relapse, clinical relapse, and HBsAg loss were 55...
December 26, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29251788/nucleic-acid-polymer-rep-2139-and-nucleos-t-ide-analogues-act-synergistically-against-chronic-hepadnaviral-infection-in-vivo
#14
Jonathan Quinet, Catherine Jamard, Madeleine Burtin, Matthieu Lemasson, Sylviane Guerret, Camille Sureau, Andrew Vaillant, Lucyna Cova
Nucleic acid polymer (NAP) REP 2139 treatment was shown to block the release of viral surface antigen in DHBV-infected ducks and in patients with chronic HBV or HBV/HDV infection. In this preclinical study, a novel combination therapy consisting of REP 2139 with tenofovir disoproxil fumarate (TDF) and entecavir (ETV) was evaluated in vivo in the chronic DHBV infection model. DHBV-infected duck groups were treated as follows: normal saline (control); REP 2139-Ca; TDF; REP 2139-Ca + TDF; REP 2139-Ca + TDF + ETV...
December 18, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29249417/quantification-of-serum-hepatitis-b-core-antibody-to-predict-off-entecavir-relapse-in-patients-with-chronic-hepatitis-b
#15
Cheng-Hao Tseng, Yao-Chun Hsu, Chi-Yang Chang, Tai-Chung Tseng, Ming-Shiang Wu, Jaw-Town Lin, Jia-Horng Kao
BACKGROUND/PURPOSE: The predictors of off-therapy response in patients treated with neucleos(t)ide analogue (NA) have not been elucidated. It remained unexplored whether serum level of hepatitis B core antibody (anti-HBc) at the end of NA therapy was associated with relapse risks. METHODS: This prospective study monitored 82 chronic hepatitis B (CHB) patients after discontinuing entecavir. All patients had been treated for 3 years or longer and serologically negative for viral DNA and HBeAg at treatment cessation...
December 14, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/29235226/reduced-therapeutic-effect-of-antiviral-drugs-in-patients-with-hepatitis-b-virus-reactivation-after-hematopoietic-stem-cell-transplantation
#16
Masamichi Kimura, Koji Nishikawa, Hisashi Sakamaki, Masashi Mizokami, Kiminori Kimura
BACKGROUND: Patients with resolved Hepatitis B virus (HBV) infection following hematopoietic stem cell transplantation (HSCT) are potentially at high risk of HBV reactivation. Although anti-viral drug therapy is recommended when HBV DNA reappears in the serum, drug efficacy after HBV reactivation remains unclear. METHODS: Host immune response against HBV was investigated via immunological analyses at 12 months after entecavir (ETV) treatment in six HSCT-treated and five non-HSCT-treated patients with HBV reactivation, and 18 patients with chronic hepatitis B (CHB)...
December 13, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29228565/nucleoside-analogs-treatment-delay-the-onset-of-hepatocellular-carcinoma-in-patients-with-hbv-related-cirrhosis
#17
Jingfeng Bi, Zheng Zhang, Enqiang Qin, Jun Hou, Shuiwen Liu, Zengmin Liu, Shuo Li, Zhenman Wei, Yanwei Zhong
Whether Nucleos(t)ide analogs(NA) treatment can delay the onset of HCC remains unclear. We retrospectively analyzed the clinical data of patients with HBV-related cirrhosis and HCC from 2000 to 2012. Cox proportional hazards model was used to explore the association between NA treatment and postponement of HCC development, the dependent variable was time interval from cirrhosis treatment towards the onset of HCC, and the covariates included age, sex, family history, compensation status at baseline. A total of 1155 HCC patients treated with NAs (n = 528, lamivudine, adefovir, entecavir) and non NA (n = 627) for more than 24 months before the occurrence of HCC were incorporated into the cohort...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228519/large-scale-surveillance-study-of-the-safety-and-effectiveness-of-entecavir-in-korean-patients-with-chronic-hepatitis-b
#18
Chang Wook Kim, Chang Seop Kim, Hee Yeon Kim, Chang Don Lee, Kyungha Yu, Cyril Llamoso, Heon Ju Lee
Background/Aims: Entecavir (ETV) is effective and safe antiviral agent against hepatitis B virus (HBV) in clinical and real-world setting but, most studies were performed in single institute or have limitation in patient's number. A large-scale nation-wide real-world surveillance study was carried out to investigate safety, efficacy and clinical effectiveness of ETV in Korean patients with chronic hepatitis B (CHB). Methods: Between 2006 and 2012, 3,444 patients were enrolled from 132 Korean institutions...
December 13, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29198095/is-it-possible-to-predict-the-development-of-an-entecavir-resistance-mutation-in-patients-with-chronic-hepatitis-b-in-clinical-practice
#19
Joon Yeul Nam, Jeong-Hoon Lee
No abstract text is available yet for this article.
December 4, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29194870/delayed-viral-suppression-during-antiviral-therapy-is-associated-with-increased-hepatocellular-carcinoma-rates-in-hbeag-positive-high-viral-load-chronic-hepatitis-b
#20
Joon Yeul Nam, Young Chang, Hyeki Cho, Seong Hee Kang, Young Youn Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
The treatment option in chronic hepatitis B (CHB) patients with persistent low-level viremia despite entecavir or tenofovir monotherapy is unclear. This study investigated the development of hepatocellular carcinoma (HCC) or cirrhosis in hepatitis B e antigen (HBeAg) positive high viral load CHB patients, according to the time needed to achieve complete viral suppression. A total of 325 HBeAg-positive CHB patients with high viral load who were recently started on antiviral therapy with entecavir or tenofovir were included...
December 1, 2017: Journal of Viral Hepatitis
keyword
keyword
2107
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"